Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2002 1
2008 2
2011 2
2012 6
2013 10
2014 26
2015 22
2016 31
2017 20
2018 31
2019 43
2020 56
2021 51
2022 41
2023 41
2024 19

Text availability

Article attribute

Article type

Publication date

Search Results

337 results

Results by year

Filters applied: . Clear all
Page 1
Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.
Foà R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo MC, Canichella M, Viero P, Ferrara F, Lunghi M, Fabbiano F, Bonifacio M, Fracchiolla N, Di Bartolomeo P, Mancino A, De Propris MS, Vignetti M, Guarini A, Rambaldi A, Chiaretti S; GIMEMA Investigators. Foà R, et al. N Engl J Med. 2020 Oct 22;383(17):1613-1623. doi: 10.1056/NEJMoa2016272. N Engl J Med. 2020. PMID: 33085860 Clinical Trial.
Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial.
Bassan R, Chiaretti S, Della Starza I, Spinelli O, Santoro A, Paoloni F, Messina M, Elia L, De Propris MS, Scattolin AM, Audisio E, Marbello L, Borlenghi E, Zappasodi P, Mauro E, Martinelli G, Mattei D, Fracchiolla N, Bocchia M, De Fabritiis P, Bonifacio M, Candoni A, Cassibba V, Di Bartolomeo P, Latte G, Trappolini S, Guarini A, Vitale A, Fazi P, Piciocchi A, Rambaldi A, Foà R. Bassan R, et al. Blood Adv. 2023 Aug 22;7(16):4448-4461. doi: 10.1182/bloodadvances.2022009596. Blood Adv. 2023. PMID: 37276451 Free PMC article.
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).
Stahl M, Bewersdorf JP, Xie Z, Porta MGD, Komrokji R, Xu ML, Abdel-Wahab O, Taylor J, Steensma DP, Starczynowski DT, Sekeres MA, Sanz G, Sallman DA, Roboz GJ, Platzbecker U, Patnaik MM, Padron E, Odenike O, Nimer SD, Nazha A, Majeti R, Loghavi S, Little RF, List AF, Kim TK, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Gore SD, Greenberg P, Figueroa ME, Fenaux P, Efficace F, DeZern AE, Daver NG, Churpek JE, Carraway HE, Buckstein R, Brunner AM, Boultwood J, Borate U, Bejar R, Bennett JM, Wei AH, Santini V, Savona MR, Zeidan AM. Stahl M, et al. Blood Rev. 2023 Nov;62:101128. doi: 10.1016/j.blre.2023.101128. Epub 2023 Aug 19. Blood Rev. 2023. PMID: 37704469 Review.
Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting.
Attardi E, Savi A, Borsellino B, Piciocchi A, Cipriani M, Ottone T, Fabiani E, Divona M, Travaglini S, Pascale MR, Awada H, Durmaz A, Visconte V, Della Porta MG, Venditti A, Maciejewski JP, Gurnari C, Voso MT. Attardi E, et al. Blood Adv. 2023 Sep 12;7(17):5122-5131. doi: 10.1182/bloodadvances.2023010173. Blood Adv. 2023. PMID: 37327116 Free PMC article.
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.
Zeidan AM, Platzbecker U, Bewersdorf JP, Stahl M, Adès L, Borate U, Bowen D, Buckstein R, Brunner A, Carraway HE, Daver N, Díez-Campelo M, de Witte T, DeZern AE, Efficace F, Garcia-Manero G, Garcia JS, Germing U, Giagounidis A, Griffiths EA, Hasserjian RP, Hellström-Lindberg E, Iastrebner M, Komrokji R, Kulasekararaj AG, Malcovati L, Miyazaki Y, Odenike O, Santini V, Sanz G, Scheinberg P, Stauder R, van de Loosdrecht AA, Wei AH, Sekeres MA, Fenaux P. Zeidan AM, et al. Blood. 2023 Apr 27;141(17):2047-2061. doi: 10.1182/blood.2022018604. Blood. 2023. PMID: 36724453 Free article.
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial.
Lübbert M, Wijermans PW, Kicinski M, Chantepie S, Van der Velden WJFM, Noppeney R, Griškevičius L, Neubauer A, Crysandt M, Vrhovac R, Luppi M, Fuhrmann S, Audisio E, Candoni A, Legrand O, Foà R, Gaidano G, van Lammeren-Venema D, Posthuma EFM, Hoogendoorn M, Giraut A, Stevens-Kroef M, Jansen JH, de Graaf AO, Efficace F, Ammatuna E, Vilque JP, Wäsch R, Becker H, Blijlevens N, Dührsen U, Baron F, Suciu S, Amadori S, Venditti A, Huls G; EORTC Leukemia Group, GIMEMA, and German MDS Study Group. Lübbert M, et al. Lancet Haematol. 2023 Nov;10(11):e879-e889. doi: 10.1016/S2352-3026(23)00273-9. Lancet Haematol. 2023. PMID: 37914482 Free article. Clinical Trial.
Health-related Quality of Life Profile of Newly Diagnosed Patients With Myelodysplastic Syndromes by Age, Sex, and Risk Group: A Real-world Study by the GIMEMA.
Efficace F, Al Essa W, Platzbecker U, Niscola P, Palumbo GA, Caocci G, Cottone F, Breccia M, Luppi M, Stauder R, Ricco A, Petranovic D, Baron F, Voso MT, Fianchi L, Frairia C, Capodanno I, Sarlo C, Fedele M, Lemoli RM, Invernizzi R, Vallisa D, Di Renzo N, Fozza C, Doro M, Giesinger JM, Vignetti M. Efficace F, et al. Hemasphere. 2023 Aug 30;7(9):e944. doi: 10.1097/HS9.0000000000000944. eCollection 2023 Sep. Hemasphere. 2023. PMID: 37663671 Free PMC article.
Early Palliative Care in Acute Myeloid Leukemia.
Potenza L, Borelli E, Bigi S, Giusti D, Longo G, Odejide O, Porro CA, Zimmermann C, Efficace F, Bruera E, Luppi M, Bandieri E. Potenza L, et al. Cancers (Basel). 2022 Jan 18;14(3):478. doi: 10.3390/cancers14030478. Cancers (Basel). 2022. PMID: 35158746 Free PMC article. Review.
337 results